The Biostatisfics and Infomatics Core (BIC) brings together biostatistical, informatics and database experts to support the informafion and analysis needs ofthe individual SPORE projects, cores, and leadership. The BIC serves two key roles. The first is to provide basic statisfical analysis support to all projects and cores. Highlights of this activity in the past have been the development of procedures for quality control and normalizafion of high throughput bead-based assay platforms, and statisfical methods for combining, evaluafing and using biomarkers in screening studies. The second key role includes managing the data from projects and cores. Highlights of this acfivity has been the development of a comprehensive informatics system that currently maintains data for over 200,000 unique specimens from 3000 women enrolled in our studies, including all associated clinical, epidemiological and research assay data, and coordinafion of several inter-spore collaborations. ' During the next phase the BIC will continue to manage each project's information needs and assist in facilitating high quality data analysis. Specific statistical research support will include the revision of methods for using mulfiple biomarkers over fime in a screening study (prospective screening project), and development of statisfical techniques for the discovery of multigene Component Patterns (CPs). Specific developments for data management include new methods for management of specimen repository data (all projects), expanding the web-based Informatics System to support the work of the Informatics Coordinating Center for Project 1's Novel Markers Randomized Control Trial, expanding support to manage Phase 1 clinical trials described in Projects 2 and 5, and complefing our efforts to obtain caBlG compliance. Because ofthe experience and capabilities ofthe BIC Informatics System, we were selected by GenoLogics to serve as a development partner for their next-generafion comprehensive information system, including components of sample tracking, query, and data sharing. With support from the Canary Foundafion and FHCRC we will transifion to the GenoLogics platform in 2009. GenoLogics will market their system worldwide.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications